Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sevelamer carbonate - Sanofi Genzyme

Drug Profile

Sevelamer carbonate - Sanofi Genzyme

Alternative Names: GZ 419831; Renvela

Latest Information Update: 27 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Epoxy compounds; Polyamines; Small molecules
  • Mechanism of Action Chelating agents; Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 16 Aug 2019 Sanofi completes the phase III RECOVER trial for Hyperphosphataemia in China (PO, Tablet) (NCT03001011)
  • 21 Dec 2016 Sanofi plans the phase III RECOVER trial for Hyperphosphataemia in China (PO, Tablet) (NCT03001011)
  • 01 Jun 2015 Genzyme completes a phase II trial in Hyperphosphataemia (In adolescents, In children, In infants) in Poland, Lithuania, Germany, France and USA (NCT01574326)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top